Synthetic adenosine monophosphate analog is also known as 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). Studies suggest that its primary purpose may be to increase AMPK activity, an enzyme in cellular energy metabolism. In the context of cardiac injury, it is being studied for its protective potential in the context of ischemia damage to cardiac myocytes. The enzyme and protein complex known as AMP-activated protein kinase may control multiple metabolic pathways. Research suggests its expression has been detected in various tissues, including the skeletal muscles, liver, and brain. Potentially, it inhibits cholesterol production and ketogenesis across all of these tissues. Insulin secretion and glucose absorption in skeletal muscle may also be affected. Hypoxia and hypoglycemia are only two examples of energy deficit situations that might activate AMPK.
AICAR Peptide and the Heart
Studies on AICAR have focused on its possible two-way protective function in preventing cardiac ischemia caused by cardiovascular disease. Like other heart disorders, Atherosclerosis is thought to have inflammation as a major factor in its disease pathophysiology. Studies in rabbits suggested that AICAR might inhibit the growth of vascular smooth muscle. In addition to improving the heart’s function, reducing vascular inflammation may lessen the likelihood of immediate and delayed problems after stent implantation. One of the immunological responses that may precipitate a heart attack is macrophage multiplication in response to high LDL (bad cholesterol) levels. It has been hypothesized that AICAR may dampen this immunological reaction.
Researchers have investigated AICAR for its possible protective effects after a heart attack, with preliminary findings suggesting the peptide may function by postponing cell death via preconditioning. On the other hand, AICAR in an ischemic heart has been hypothesized to decrease infarct occurrence and size by up to 25%, and it may help increase the overall blood flow to the heart.
One research aimed to learn more about how activating AMPK can help myocardial glycogenolysis. It seems that intact hearts from halothane-anesthetized mouse models were used in the investigations. AICAR, an adenosine analog hypothesized to activate AMPK and perhaps penetrate cells, was perfused into the hearts alone or in combination with other agents. Findings implied that AICAR may have accelerated myocardial glycogen destruction (glycogenolysis), although glycogen synthesis seemed unaffected. Based on these results, AMPK activation may play a distinct function in glycogenolysis. The active intracellular form of AICAR, 5-aminoimidazole-4-carboxamide 1-beta-d-ribofuranotide (ZMP), was also speculated to be elevated in cardiac tissue after AICAR presentation. AICAR did not seem to influence the levels of glucose-6-phosphate or adenine nucleotides in freeze-clamped tissue, nor did it appear to impact the activity of glycogen synthase (GS) or glycogen phosphorylase (GP) when evaluated in tissue homogenates. This study suggests that ZMP may conceivably allosterically activate GP, perhaps leading to glycogenolysis in the intact murine model heart.
AICAR Peptide and Insulin Sensitivity
Reduced insulin sensitivity in skeletal muscles and increased absorption in adipose tissue are blamed for insulin resistance, contributing to systemic inflammation. Increases in insulin and blood sugar arise from this process. Reducing inflammation has been linked to better glucose homeostasis and insulin sensitivity. Possible anti-inflammatory effects of AICAR in many metabolic pathways have been linked to enhanced insulin sensitivity and lipid metabolism. AICAR has been theorized to lower blood glucose levels in diabetic mice models, possibly without causing weight loss. AICAR seems to replicate the impact that physical activity has on glucose absorption by muscles. Muscle GLUT-4 receptors may be stimulated, which play a crucial role in glucose absorption.
Another research study used mouse models to examine how AMPK activation might mitigate the onset of obesity-related diabetes and the underlying processes involved. Many of the positive impact of physical activity on glucose and lipid metabolism are thought to be mediated by AMPK, a critical regulator of these processes. As a genetic subject of type 2 diabetes, male Zucker diabetic fatty (ZDF) mice models were used to examine the effects of chronic phyiscal activity and AMPK activation. Over 8 weeks, these murine models were exposed to either daily running activities or AICAR, thought to activate AMPK. They were then put under scrutiny alongside a control group. The research results suggested that, unlike the control group, neither the exercised nor the AICAR murine models appeared to develop hyperglycemia (high blood sugar levels) throughout the intervention.
When comparing the exercised and AICAR murine models to the control ZDF murine models, it suggests that whole-body insulin sensitivity, which refers to the murine model’s capacity to react to and use insulin efficiently, may have been enhanced in the former two. As a result of this increase in insulin sensitivity, glucose metabolism, and insulin resistance may have improved, both of which have a role in developing type 2 diabetes.
Furthermore, in both the exercised and AICAR murine models, the morphology of pancreatic beta cells, which are responsible for insulin production, appeared virtually normal. This finding supports the hypothesis that prolonged AMPK activation might aid in preserving beta-cell function, which is often compromised in type 2 diabetes. Considering all these aspects, it may be argued that “activation of AMPK may represent a therapeutic approach to improve insulin action and prevent a decrease in beta-cell function associated with type 2 diabetes.”
AICAR Peptide and Fertility
Much of the study time spent on AICAR has focused on its potential to increase sperm count in male research models. Several mouse model studies have purported that activating AMPK may boost fecundity. Since AICAR is theorized to be a useful AMPK activator, its long-term impact may potentially enhance sperm motility. Specialists propose that the presentation of AICAR may have the potential to profoundly influence fertilization since it may control the activity of all the active enzymes involved in sperm motility.
AICAR Peptide and Inflammation
At the cellular level, activation of AMPK seems to have an anti-inflammatory impact. Several illnesses’ origin stories include inflammation in some way. The same holds for diabetes, which means AICAR might be studied in the context of this disease. However, its anti-inflammatory potential in disease processes is not exhausted here. Animal studies have proposed promising results, suggesting it may aid various inflammatory diseases. In sum, AICAR’s potential cardioprotective effects should not be discounted. Possible properties of metabolic function and related issues have been investigated.
Researchers interested in peptides for sale online may find the highest quality research compounds from Core Peptides.
[i] Corton, J. M., Gillespie, J. G., Hawley, S. A., & Hardie, D. G. (1995). 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. European journal of biochemistry, 229(2), 558–565. https://doi.org/10.1111/j.1432-1033.1995.tb20498.x
[ii] Sun, N., Youle, R. J., & Finkel, T. (2016). The Mitochondrial Basis of Aging. Molecular cell, 61(5), 654–666. https://doi.org/10.1016/j.molcel.2016.01.028
[iii] Stone, J. D., Narine, A., & Tulis, D. A. (2012). Inhibition of vascular smooth muscle growth via signaling crosstalk between AMP-activated protein kinase and cAMP-dependent protein kinase. Frontiers in physiology, 3, 409. https://doi.org/10.3389/fphys.2012.00409
[iv] Ishii, N., Matsumura, T., Kinoshita, H., Motoshima, H., Kojima, K., Tsutsumi, A., Kawasaki, S., Yano, M., Senokuchi, T., Asano, T., Nishikawa, T., & Araki, E. (2009). Activation of AMP-activated protein kinase suppresses oxidized low-density lipoprotein-induced macrophage proliferation. The Journal of biological chemistry, 284(50), 34561–34569. https://doi.org/10.1074/jbc.M109.028043
[v] Longnus, S. L., Wambolt, R. B., Parsons, H. L., Brownsey, R. W., & Allard, M. F. (2003). 5-Aminoimidazole-4-carboxamide 1-beta -D-ribofuranoside (AICAR) stimulates myocardial glycogenolysis by allosteric mechanisms. American journal of physiology. Regulatory, integrative and comparative physiology, 284(4), R936–R944. https://doi.org/10.1152/ajpregu.00319.2002
[vi] Buhl, E. S., Jessen, N., Pold, R., Ledet, T., Flyvbjerg, A., Pedersen, S. B., Pedersen, O., Schmitz, O., & Lund, S. (2002). Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes, 51(7), 2199–2206. https://doi.org/10.2337/diabetes.51.7.2199